ChemoCentryx Inc (NASDAQ:CCXI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday.

According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “

Several other analysts have also recently commented on CCXI. JMP Securities initiated coverage on ChemoCentryx in a report on Tuesday, February 21st. They issued an “outperform” rating for the company. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a report on Wednesday, March 15th.

Shares of ChemoCentryx (NASDAQ:CCXI) traded down 0.26% during mid-day trading on Monday, reaching $7.66. 65,922 shares of the company traded hands. ChemoCentryx has a 52-week low of $1.92 and a 52-week high of $9.10. The firm’s 50 day moving average price is $6.88 and its 200-day moving average price is $6.82. The company’s market capitalization is $368.85 million.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. Equities analysts predict that ChemoCentryx will post ($1.06) earnings per share for the current fiscal year.

Your IP Address:

In other ChemoCentryx news, insider Markus J. Cappel sold 26,821 shares of ChemoCentryx stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $7.51, for a total value of $201,425.71. Following the completion of the sale, the insider now owns 20,833 shares in the company, valued at approximately $156,455.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 26.80% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of CCXI. Acrospire Investment Management LLC boosted its stake in shares of ChemoCentryx by 192.9% in the third quarter. Acrospire Investment Management LLC now owns 31,040 shares of the biopharmaceutical company’s stock worth $187,000 after buying an additional 20,441 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of ChemoCentryx during the third quarter worth about $296,000. Geduld E E boosted its stake in shares of ChemoCentryx by 100.0% in the third quarter. Geduld E E now owns 50,000 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 25,000 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of ChemoCentryx during the fourth quarter worth about $483,000. Finally, Federated Investors Inc. PA boosted its stake in shares of ChemoCentryx by 6,468.9% in the fourth quarter. Federated Investors Inc. PA now owns 92,096 shares of the biopharmaceutical company’s stock worth $682,000 after buying an additional 90,694 shares during the last quarter. Institutional investors and hedge funds own 48.16% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

5 Day Chart for NASDAQ:CCXI

Get a free copy of the Zacks research report on ChemoCentryx (CCXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChemoCentryx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc and related companies with MarketBeat.com's FREE daily email newsletter.